ICON Announces the Appointment of Dr. Steve Cutler to Board of
Directors

November 25, 2015 06:00 AM Eastern Standard Time

DUBLIN--(BUSINESS WIRE)--ICON
plc, (NASDAQ:ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced the appointment of Dr. Steve Cutler
to the ICON Board of Directors.

Dr. Cutler joined ICON in 2011 as Group President, ICON Clinical
Research Services. Dr. Cutler successfully led this business to
significant growth and, as a result, was promoted to Chief Operating
Officer in January 2014. As Chief Operating Officer, Dr. Cutler has
responsibility for all of ICON’s operational service areas, including
clinical research, early phase, laboratories, DOCS resourcing and
commercialisation and outcomes. Dr. Cutler’s operational leadership as
Chief Operating Officer has helped ICON successfully deliver innovative
and integrated services and solutions to customers.

Prior to joining ICON, Dr. Cutler was Chief Executive Officer of Kendle.
Prior to Kendle, Dr. Cutler held various senior roles in both Quintiles
and Sandoz (now Novartis). Dr. Cutler holds a B.Sc. and a Ph.D from the
University of Sydney and a Masters of Business Administration from the
University of Birmingham (UK).

“Since joining ICON in 2011, Dr. Cutler has made a significant
contribution to ICON and our journey towards becoming the trusted
partner in drug development,” commented Mr. Thomas Lynch, Chairman
of ICON. “I am delighted to now welcome Dr. Cutler to the ICON Board
and I look forward to his continued success with and contribution to
ICON.”

About ICON plc

ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 77 locations in 38 countries and
has approximately 11,700 employees.

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.